{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:58:45Z","timestamp":1790492325252,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eururo.2026.04.030","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:41:46Z","timestamp":1778902906000},"page":"191-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combining ctDNA and utDNA as a Dual Biomarker-driven Strategy for Bladder-sparing Therapy in Muscle-invasive Bladder Cancer: Neither Alone Is Sufficient"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-8174","authenticated-orcid":false,"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Gonz\u00e1lez-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.04.030_b0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.030_b0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.030_b0015","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2533449123","article-title":"Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer","volume":"123","author":"Galsky","year":"2026","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2026.04.030_b0020","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1158\/1078-0432.CCR-25-3712","article-title":"ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer","volume":"32","author":"Epstein","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.04.030_b0025","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41591-026-04271-3","article-title":"Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial","volume":"32","author":"Mellema","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.04.030_b0030","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO-25-02382","article-title":"Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in muscle-invasive bladder cancer: SunRISe-4 primary analysis and biomarker results","volume":"44","author":"Necchi","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.030_b0035","doi-asserted-by":"crossref","unstructured":"Gabriel PE, Marcq G, Zhu A, Sfakianos JP, Xylinas E. Circulating plasma and urine tumor DNA in non-muscle-invasive bladder cancer: a promising biomarker to guide therapeutic intensification. Eur Urol Open Sci. In press. https:\/\/doi.org\/10.1016\/j.euros.2026.02.003.","DOI":"10.1016\/j.euros.2026.02.003"},{"key":"10.1016\/j.eururo.2026.04.030_b0040","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.04.030_b0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41568-025-00882-z","article-title":"Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization","volume":"26","author":"Ward","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2026.04.030_b0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS880","article-title":"EORTC GUCG 2418 - STARBURST: strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies - an EORTC platform trial","volume":"43","author":"Grisay","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.030_b0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS890","article-title":"NEO-BLAST: neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment","volume":"43","author":"St-Laurent","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.030_b0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS885","article-title":"EV-PRIME: phase Ib\/II study of enfortumab vedotin and pembrolizumab combined with radiotherapy as a bladder-sparing trimodality therapy in muscle invasive bladder cancer","volume":"44","author":"Koshkin","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.030_b0065","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.2026.44.7_suppl.636","article-title":"Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in Niagara","volume":"44","author":"Van Der Heijden","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.030_b0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA632","article-title":"Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): integrated analysis of the RETAIN trials","volume":"44","author":"Ghatalia","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.030_b0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.annonc.2025.12.018","article-title":"ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial","volume":"37","author":"Dyrskj\u00f8t","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.030_b0080","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.030_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2023.100007","article-title":"Circulating tumor DNA in clinical trials for solid tumors: challenges and current applications","volume":"1","author":"Parisi","year":"2023","journal-title":"J Liq Biopsy"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:27:28Z","timestamp":1788740848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826021548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0302283826021548"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.030","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining ctDNA and utDNA as a Dual Biomarker-driven Strategy for Bladder-sparing Therapy in Muscle-invasive Bladder Cancer: Neither Alone Is Sufficient","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}